Drug Minkang announces successful acquisition of US clinical research firm ResearchPoint Global (RPG)

Today (October 18), Pharmaceuticals announced its successful acquisition of ResearchPoint Global (RPG), a US clinical research firm. Upon completion of the merger, RPG will become a wholly owned subsidiary of Pharmaceutical Mingkang Group and continue to focus on improving its core competitiveness in order to provide customers with better service. The acquisition is aimed at expanding Theronic's clinical research services capabilities in the U.S. and around the world, and further improving and expanding PharmaceuticalSamine's integrated research and development service platform.
with the completion of this strategic acquisition, RPG will be integrated with the existing China Clinical Research Services Team (Kant Hongyi) of Pharmaceutical Mingkang Group to provide customers with globally integrated clinical development services. At present, RPG has established good strategic partnerships with research and development institutions in North America, Europe, Africa, Asia Pacific and Israel. As part of the open empowerment platform, the Group's Kant hiroshi already has a 500-person business team, and SMO-Jinshi Pharmaceuticals has a team of clinical research coordinators (CRCs) of more than 1,000 people. Both teams have extensive experience in clinical research services in China.
State Food and Drug Administration (CFDA) recently promulgated a series of drug medical device review and approval system reform measures, with special reference to the acceptance of overseas clinical trial data, which will bring unprecedented opportunities for innovative institutions around the world. The collaboration between Pharmaceuticals and RPG will help drive and integrate regional and global clinical research processes.about RPG
founded in 1999 and headquartered in Austin, Texas. As a company offering a full range of clinical research services, RPG has a highly flexible and experienced team that provides global partners with integrated services including project management, research center site selection and site management, drug safety and medical monitoring, clinical monitoring, data management, biostatistics, and medical writing, covering all stages of clinical development and providing business radiation to more than 60 countries and regions around the world.
, Chairman and Chief Executive Officer of The Drug Minkang, said: "We warmly welcome RPG's addition. Over the past 20 years, John has led RPG to grow into a reputable company in the industry, with extensive global clinical development experience and a network of services that provide a solid foundation for our ability to build a globally integrated professional clinical service platform. This acquisition is also an important milestone in our vision for Pharmaceuticals, and we remain committed to building the highest, widest and deepest enabling platform in the global pharmaceutical and health industry to help global innovation partners develop pharmaceutical products faster and better. ”